News | August 09, 2023
Hikal posts Q1 FY 24 consolidated PAT at Rs. 6.92 Cr
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
Injectafer is now the first and only intravenous (IV) iron replacement therapy indicated for adult patients with heart failure who have iron deficiency
Farxiga is expected to have such a strong influence on the market due to the impressive results
VEOZAH is first-in-class treatment option to reduce the frequency and severity of moderate to severe VMS due to menopause
It will help in bringing a significant benefit in compliance of ARV medication in the paediatric HIV treatment
The committee voted that FDA should restrict use of LYNPARZA plus abi/pred to these BRCAm mCRPC patients
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
Subscribe To Our Newsletter & Stay Updated
